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ABSTRACT
Human BRCA2, a breast and ovarian cancer sup-
pressor, binds to the DNA recombinase RAD51
through eight conserved BRC repeats, motifs of
 30 residues, dispersed across a large region of the
protein. BRCA2 is essential for homologous recom-
bination in vivo, but isolated BRC repeat peptides
can prevent the assembly of RAD51 into active
nucleoprotein filaments in vitro, suggesting a model
in which BRCA2 sequesters RAD51 in undamaged
cells, and promotes recombinase function after DNA
damage. How BRCA2 might fulfill these dual func-
tions is unclear. We have purified a fragment of
human BRCA2 (BRCA2BRC1–8) with 1127 residues
spanning all 8 BRC repeats but excluding the
C-terminal DNA-binding domain (BRCA2CTD).
BRCA2BRC1–8 binds RAD51 nucleoprotein filaments
in a ternary complex, indicating it may organize
RAD51 on DNA. Human RAD51 is relatively ineffec-
tive in vitro at strand exchange between homolo-
gous DNA molecules unless non-physiological ions
like NH
1
4 are present. In an ionic milieu more typical
of the mammalian nucleus, BRCA2BRCI–8 stimulates
RAD51-mediated strand exchange, suggesting it
may be an essential co-factor in vivo. Thus, the
human BRC repeats, embedded within their sur-
ronding sequences as an eight-repeat unit, mediate
homologous recombination independent of the
BRCA2CTD through a previously unrecognized role
in control of RAD51 activity.
INTRODUCTION
BRCA2, a tumour suppressor whose inactivation is asso-
ciated with hereditary breast and ovarian cancer predisposi-
tion, is essential for DNA repair in mammalian cells (1–3).
BRCA2-deﬁcient cells are defective in the repair of DNA
double-strand breaks by error-free homologous recombina-
tion (4), allowing error-prone repair processes to create
gross chromosomal re-arrangements that may promote
carcinogenesis (2). The role of BRCA2 in homologous
recombination has been linked to its functions in the regula-
tion of RAD51, a RecA-related recombinase that forms the
nucleoprotein ﬁlaments on damaged DNA that are crucial
to recombinational repair (5,6). BRCA2 binds directly to
RAD51 through 6 of the 8 BRC repeats,  30 amino acid
motifs encoded within the central exon 11 region of all
known mammalian BRCA2 genes (7–9). This feature distin-
guishes mammalian BRCA2 molecules from simpler
eukaryal homologues such as Brh2 in Ustilago maydis,
which contains a single BRC repeat (10).
Available data concerning the nature and consequences of
the interaction between human BRCA2 and RAD51 mediated
by the BRC repeats raise an important but unresolved ques-
tion. On the one hand, peptides encoding isolated BRC
repeats such as BRC3 when present in excess can prevent
the assembly of RAD51 into nucleoprotein ﬁlaments on
DNA substrates, and can dissolve pre-formed RAD51 com-
plexes (11). A structural basis for this apparently inhibitory
activity is suggested by the fact that BRC repeats can bind
to RAD51 by mimicking its mode of self-association; thus
preventing multimerization and dispersing existing multimers
(12). Conversely, however, there is evidence that isolated
BRC repeat peptides under certain conditions can bind to
the RAD51 nucleoprotein ﬁlament, rather than disrupting it
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motes (rather than inhibits) RAD51 foci formation and
DNA recombination in cells (2,4,14). These observations
have been reconciled in a hypothetical model proposing
that BRCA2 sequesters RAD51 in a monomeric form
bound to BRC repeats, until activation by DNA damage
signals results in the mobilization of BRCA2–RAD51 com-
plexes, and their targeting to sites of DNA repair where
BRCA2 may promote recombination (15). Studies on the
dynamics of functional GFP–RAD51 fusion proteins in
the nuclei of living cells before and after DNA damage
offer support for this view (16), although the lack of direct
biochemical evidence that human BRCA2 is a recombination
mediator has been noted as an important hiatus in current
understanding (17).
How can BRCA2–RAD51 complexes delivered to sites of
DNA damage operate to promote repair by homologous
recombination? Whilst the function of the C-terminal domain
of BRCA2 in recombination can be rationalized by its ability
to bind DNA and stimulate RAD51-mediated strand
exchange in vitro through the displacement of the single-
strand DNA-binding protein RPA (18), the role of the BRC
repeat-containing region is less clear, given the ability of iso-
lated BRC repeat peptides to both disrupt ﬁlaments (11,12)
and bind to them (13), depending on the experimental condi-
tions. These studies—and indeed, most previous work on the
biochemical function of the BRC repeats—have utilized
isolated BRC repeat peptides. However, all mammalian
BRCA2 molecules contain eight conserved BRC repeats in
the exon 11 region (Figure 1A).
Several features of the organization of the exon 11 region,
shared across mammalian evolution, point to the fact that
isolated BRC repeat peptides may not accurately reﬂect the
biological activities of the eight BRC repeats embedded
within the context of surrounding sequences in exon 11.
First, although the exon 11 sequence that ﬂanks the BRC
repeats is poorly conserved even in close mammalian species,
the spacing that it provides between consecutive BRC repeats
has been well conserved in evolution (9). Second, there is a
considerably higher degree of sequence conservation between
the same BRC repeat of different mammalian species than
between different BRC repeats of one species (9,19). This
raises the possibility that during evolution, diverse selective
pressures have been placed on the BRC repeats at different
sites in exon 11, with each BRC repeat adopting an idiosyn-
cratic function (5,19). This is supported by evidence of differ-
ences in the functional characteristics of BRC3/BRC4 and
BRC7 in vitro (11,13). However, the practical difﬁculties of
producing either full-length mammalian BRCA2 (>3000
amino acids) or the BRC repeat-containing exon 11 region
(>1000 amino acids) in a form suitable for experimentation,
have meant that experiments have thus far been devoted to
studying the function of isolated BRC repeats rather than
the more physiologically relevant collective function of the
eight BRC repeats within the context of the exon 11 region.
To address this, we have puriﬁed a 1127 amino acid frag-
ment of human BRCA2 that contains all 8 BRC repeats
(BRCA2BRC1–8). We show here that puriﬁed BRCA2BRC1–8
forms a ternary complex with RAD51 and DNA, and is cap-
able of promoting RAD51-mediated strand exchange in vitro.
Thus, despite the apparently inhibitory effects of isolated
BRC repeats, within the framework provided by the exon
11 region, BRC repeats function to stimulate DNA recombi-
nation. This novel activity provides direct biochemical
evidence that BRCA2 functions as a mediator of homologous
recombination in mammalian cells.
MATERIALS AND METHODS
Protein expression, purification and peptide synthesis
A region of human BRCA2 corresponding to a 1127 amino
acids fragment between residues 987 and 2113 of the encoded
protein was cloned into a pET28a vector (Novagen) and
expressed in Rosetta (DE3) competent cells (Novagen).
Cells were lysed in 20 mM Tris–HCl, pH 8.0, 300 mM
NaCl and 5 mM DTT containing protease inhibitors
(Roche); the insoluble pellet was clariﬁed and washed with
20 mM Tris–HCl pH 8.0, 300 mM NaCl, 1% Triton X-100
and 5 mM DTT containing protease inhibitors (Roche). The
insoluble material was solubilized in 50 mM Tris–HCl,
pH 8.0, 8 M urea, 5 mM DTT and puriﬁed under denaturing
conditions by anion exchange using Q Sepharose HP resin
(Amersham) with elution over a NaCl gradient. The pH of
the eluted sample was reduced by dialysis in 50 mM sodium
acetate, pH 5.0, 8 M urea and 5 mM DTT and puriﬁcation
was completed by cation exchange using SP Sepharose HP
resin (Amersham) with elution over a NaCl gradient. Urea
used in the puriﬁcation was freshly deionized by passage
over AG 501-X8 (D) resin (Bio-Rad) in order to prevent pro-
tein carbamylation. The BRCA2 fragment was renatured by
dialysis in 50 mM Tris–HCl, pH 8.0, 500 mM L-arginine
and 10 mM DTT, and was subsequently transferred in to
20 mM Tris–HCl, 10% glycerol and 5 mM DTT by thorough
dialysis. The sample was concentrated using an Amicon
Ultra-4 centrifugal ﬁlter device and stored at  80 C.
BRCA2BRC1–8 protein was analysed by MALDI to exclude
carbamylation by urea.
Full-length human RAD51 was cloned into a pET11d vec-
tor (Novagen), expressed in recA
  cells BLR (DE3)
competent cells (Novagen), and puriﬁed by a method
described previously (20). Recombinant human RPA protein
was made using the expressing vector p11d-tRPA (gift from
Mark Wold) and puriﬁed in Dr Richard Wood’s lab (Cancer
Research UK Clare Hall Labs) as described previously (21).
Protein concentrations were estimated by UV absorbance
at 280 nm (Varian Cary 50 spectrophotometer) with extinc-
tion coefﬁcients estimated by ProtParam (22).
The BRC4 repeat peptide (KEPTLLGFHTASGKKVKTA-
KESLDKVKNLFDEKEQ) was synthesized at the Cancer
Research UK Peptide Synthesis Unit, London. Stock
solutions of the peptides dissolved in dH2O and stored at
 20 C were diluted appropriately for strand exchange assays.
Co-immunoprecipitation
Protein A–Sepharose 6 M (50 ml) (Sigma) was incubated with
20 mg rabbit polyclonal anti-RAD51 IgG (Santa Cruz Bio-
tech) or with 20 mg non-immune rabbit serum IgG for 3 h
at 4 C in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl and 1%
Triton X-100. The resulting complexes were then incubated
Nucleic Acids Research, 2006, Vol. 34, No. 14 4001with the puriﬁed BRCA2 fragment (0.9 mM) and/or puriﬁed
human RAD51 (0.9 mM) in the presence of 10 mg/ml BSA
(Sigma) in 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% Tri-
ton X-100 at 4 C for 3 h. The complexes were thoroughly
washed in buffer containing 500 mM NaCl and subsequent
pellets were suspended in loading buffer for analysis by
SDS–PAGE (Invitrogen).
Co-immunoprecipitation reactions were also performed
using anti-BRCA2 antibodies (Ab-1; Calbiochem) through
the method described above but using 2 mg antibodies and
with 10 nM BRCA2BRC1–8 and 1 nm, 10 or 100 nM
RAD51. Further reactions were performed using 2 mga n t i -
BRCA2 antibodies with 0.1 mMB R C A 2 BRC1–8 and 0.05,
0.1, 0.5 or 1.0 mM RAD51. These reactions were visualized
by western blot; samples were run on an SDS–PAGE gel (Invi-
trogen) and transferred on to nitrocellulose membrane (Invitro-
gen) at 25 mV for 90 min using transfer buffer 20 mM Tris,
150 mM glycine, 1% SDS and 20% methanol. The membrane
was blocked in 50 ml blocking buffer [phosphate-buffered sal-
ine (PBS), 0.05% Tween and 10% milk powder] for 1 h at
room temperature. It was then incubated with 2 mgm o u s e
monoclonal anti-BRCA2 antibodies or 2 mg rabbit polyclonal
anti-RAD51 IgG (Santa Cruz Biotech) in 20 ml blocking
buffer for 1 h, before being washed three times in washing buf-
fer (PBS and 0.05% Tween), each for 10 min. The membrane
was then incubated with 2 mg alkaline phosphatase conjugated
Figure 1. Expression and purification of a 1127 amino acid fragment of BRCA2 containing all 8 BRC repeats. (A) Human BRCA2 is a large protein of 3418
amino acids that can be divided into three general regions: an N-terminal region of unknown function, a central exon 11 region and a C-terminal DNA-binding
domain (in addition to an extreme C-terminal RAD51-binding site encoded by exon 27). The eight RAD51-binding BRC repeats are located well spaced from
one another amidst the long and divergent exon 11 region. We cloned and expressed a 1127 amino acid fragment of human BRCA2 corresponding to amino acid
residues 987–2113 and spanning all 8 BRC repeats (BRCA2BRC1–8). (B) The 126 kDa BRCA2BRC1–8 protein was expressed in E.coli as an insoluble protein; it
was purified under denaturing conditions by anionic exchange chromatography using Q Sepharose, and then cationic exchange chromatography using SP
Sepharose. The resulting purified denatured sample was renatured in a buffer containing 500 mM L-arginine and was then soluble and stable after dialysis into a
standard protein buffer. (C) Co-immunoprecipitation of purified BRCA2BRC1–8 with human RAD51; purified BRCA2 and/or purified RAD51 were incubated
with pre-formed complexes of protein A–Sepharose and rabbit polyclonal anti-RAD51 antibodies or non-immune rabbit serum IgG. The resulting complexes
were visualized by SDS–PAGE and protein staining with SimplyBlue, showing that the purified BRCA2BRC1–8 protein is functional in RAD51 binding. (D)A n
interaction between BRCA2BRC1–8 and RAD51 is further confirmed by co-immunoprecipitation anti-BRCA2 antibodies (visualized by western blot using anti-
RAD51 antibodies). BRCA2BRC1–8 (10 nM) was incubated with 1–100 nM RAD51 before immunoprecipitation using pre-formed complexes of protein
A–Sepharose and anti-BRCA2 or control irrelevant IgG. (E) The RAD51-binding capacity of BRCA2BRC1–8 was tested through an immunoprecipitation of
BRCA2BRC1–8 (0.1 mM) with anti-BRCA2 antibodies, in the presence of 0.05, 0.1, 0.5 and 1.0 mM RAD51 (providing molar ratios of 0.5, 1, 5 and 10:1).
Increasing amounts of RAD51 were co-immunoprecipitated at molar ratios between 0.5:1 and 5:1 (detected using anti-RAD51 antibodies), with binding
saturation between 5:1 and 10:1. This suggests the presence of multiple RAD51-binding sites within each BRCA2BRC1–8 molecule.
4002 Nucleic Acids Research, 2006, Vol. 34, No. 14anti-mouse antibody (Promega) or 2 mg alkaline phosphatase
conjugated anti-rabbit antibody (Promega) in 20 ml blocking
buffer for 1 h, before being washed three times in washing buf-
fer (PBS and 0.05% Tween), each for 10 min. The blot was
then developed by the addition of one SigmaFAST  BCIP/
NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetra-
zolium) tablet dissolved in 10 ml water.
Circular dichroism spectroscopy
The BRCA2BRC1–8 sample was prepared for CD analysis by
dialysis into 10 mM phosphate buffer (pH 7.5) and concentration
was conﬁrmed by absorbance at 280 nm, measured on a
Varian Cary 50 spectrophotometer. CD spectra were obtained
using a JASCO J-810 CD spectrometer. A native far UV CD
spectrum was recorded over the range 185–260 nm using
a 0.16 mg/ml sample in a cuvette of path length 0.05 cm.
A denatured far UV CD spectrum was also recorded of a
0.16 mg/ml sample in the presence of 6 M guanidine–HCl
(Fluka). CD data were converted from theta machine units
to mean residue ellipticity and were deconvoluted using the
CDSSTR algorithm of the DichroWeb server (23,24).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described previously (13) either by
pre-incubating RAD51 and BRCA2BRC1–8 before incubation
with radiolabelled DNA, or by adding BRCA2BRC1–8 to
pre-formed RAD51–DNA complexes. In the ﬁrst instance,
RAD51 (5 mM) was pre-incubated in the absence or presence
of varying concentrations of BRCA2BRC1–8 for 15 min at
37 C in Buffer A (see Strand Exchange Assay) containing
KCl to a ﬁnal concentration of 200 mM and 1 mM
AMP-PNP. ApaL1 linearized
32P-labelled dsfX174 DNA
(10 mM) was added, and the reaction was incubated at
37 C for a further 60 min. In the second instance, RAD51
(5 mM) was ﬁrst incubated at 37 C for 5 min, before
10 mM of ApaL1 linearized
32P-labelled dsfX174 DNA
was added, and the protein–DNA complex allowed to form
for 10 min at 37 C before the addition of varying concentra-
tions of BRCA2BRC1–8. Reactions were incubated at 37 C for
60 min. Control reactions with DNA alone, or DNA plus
BRCA2BRC1–8 were incubated for 75 min at 37 C. The
protein–DNA complexes were resolved by 0.5% agarose
gel electrophoresis in TAE buffer. The dried gels were
exposed to Phosphoimager screens and data processed on
the Fuji FLA5000 scanner.
Ternary complex pull-down assay
50-Biotinylated oligos (nt 5348–23) complementary to the
fX174 (+) strand were annealed to ss fX174 (+) DNA at a
ratio of 2:1, and the DNA-joint molecules were coupled to
streptavidin-conjugated magnetic beads so as to contain the
equivalent of 10 or 15 mMs sfX174 (+) DNA when incu-
bated in a 10 ml reaction in Buffer A used for strand exchange
reactions containing KCl to a ﬁnal concentration of 200 mM.
RAD51 (5 mM) in the absence or presence of the indicated
amounts of BRCA2BRC1–8 was pre-incubated in 10 ml of Buf-
fer A at 37 C for 30 min before adding to streptavidin-
conjugated magnetic beads bound to different amounts of
the DNA-joint molecules. The mixture was incubated for a
further 30 min at 37 C. Protein–DNA complexes bound to
the beads were separated out of solution using a magnetic
block. The supernatant was carefully removed into a fresh
tube containing SDS–PAGE gel loading buffer. Protein–
DNA complexes bound to the separated beads were resus-
pended in loading buffer. After heat denaturation in loading
buffer, proteins were resolved by 4–12% SDS–PAGE, and
revealed with SimplyBlue stain (Invitrogen).
Strand exchange assay
Strand exchange assays were carried out by a modiﬁcation of a
previously reported procedure (25). Reactions were assembled
in reaction Buffer A (40 mM Tris–HCl, pH 7.8, 1 mM MgCl2,
1 mM DTT, 2 mM ATP, 8 mM phosphocreatine and 25mg/ml
creatine phosphokinase). The reactions were supplemented
with either (NH4)2SO4 (100 mM ﬁnal concentration) or
KCl (200 mM ﬁnal concentration). RAD51, RPA, ssfX174
DNA, BRCA2BRC1–8 or the BRC4 peptide was included at
the concentrations described in the text and ﬁgure legends.
Reactions were incubated at 37 C as described before the
addition of either non-radiolabelled or 50-
32P-radiolabelled
ApaL1 linearized-double-stranded (lds) fX174 DNA, and
incubation at 37 C for a further 60 min. The reactions were
stopped and de-proteinized by the addition of SDS/EDTA
(0.2%/5 mM ﬁnal concentration) and Proteinase K (600 mg/
ml) and incubation at 37 C for a further 15 min. Reaction
products were separated by 1% agarose gel electrophoresis
in TAE buffer. The gels were either stained in ethidium bro-
mide (0.5 mg/ml) and visualized under UV, or dried and
exposed to Phosphoimager screens, with the results being
analysed on a Fuji FLA-5000 scanner.
RESULTS
The expression and purification of BRCA2BRC1–8
A 1127 amino acid fragment of human BRCA2 correspond-
ing to amino acid residues 987–2113 and spanning all 8 BRC
repeats (BRCA2BRC1–8; Figure 1A) was expressed in Escher-
ichia coli using a pET28a vector (Figure 1B). The 126 kDa
protein was found to be highly over-expressed in the form
of inclusion bodies. The BRCA2BRC1–8 polypeptide was
recovered from the insoluble fraction and puriﬁed under
denaturing conditions through anionic and cationic exchange
chromatography (Figure 1B). Once puriﬁed, the denatured
sample was renatured in the presence of the refolding additive
L-arginine; thereafter the BRCA2BRC1–8 protein was found to
be soluble and stable in standard protein buffers, thus allow-
ing its use in biochemical investigations. The sequence of the
puriﬁed BRCA2BRC1–8 protein was conﬁrmed and shown by
mass spectrometry to be unaffected by possible chemical
alteration due to the high concentrations of denaturant (data
not shown). The protein was found to be functional in
RAD51 binding through the co-immunoprecipitation of a
RAD51–BRCA2BRC1–8 complex using either anti-RAD51
(Figure 1C) or anti-BRCA2 (Figure 1D) antibodies. The
RAD51-binding capacity of BRCA2BRC1–8 was tested
through RAD51–BRCA2BRC1–8 co-immunoprecipitation
using anti-BRCA2 antibodies over molar ratios from 0.5:1
up to 10:1 (Figure 1E). An increasing amount of RAD51
was co-immunoprecipitated between 0.5:1 and 5:1 molar
Nucleic Acids Research, 2006, Vol. 34, No. 14 4003ratios, with binding saturation observed between 5:1 and 10:1
molar ratios. This indicates the presence of multiple RAD51-
binding sites, with each BRCA2BRC1–8 molecule binding sev-
eral RAD51 molecules.
Biophysical features of BRCA2BRC1–8
In order to investigate the conformation of BRCA2BRC1–8, the
structure of the puriﬁed protein was probed by circular
dichroism spectroscopy (Figure 2A). Far UV spectra compar-
ing renatured and denatured samples of BRCA2BRC1–8
revealed that the renatured sample does contain secondary
structural elements including both a-helices and b-sheets
(Figure 2B). Indeed, the secondary structure makeup of
BRCA2BRC1–8 was further deﬁned through the deconvolution
of a far UV spectrum over the range 185–240 nm. The sample
was found to consist of 9% a-helix, 33% b-sheet, 24% turns
and 34% random coil (data were ﬁtted with normalized
r.m.s.d. of 0.031). The ﬁnding that the BRCA2BRC1–8 protein
consists of 42% secondary structural elements and 58% turns
or random coil suggests that whilst it contains some struc-
tured regions that are potentially of functional signiﬁcance,
it is also intrinsically ﬂexible with much unordered sequence.
It is important to note that the sequence of the exon 11 region
displays in general only a moderate degree of conservation
amongst closely related BRCA2 orthologues. Whilst the
BRC repeats are themselves well conserved, the intervening
sequences between consecutive repeats are remarkably poorly
conserved. However, the length of the spacing they provide
between BRC repeats is preserved. This is consistent with a
portion of the BRCA2 exon 11 sequence constituting intrinsi-
cally unstructured ﬂexible linkers rather than structured
regions in their own right. The structural features of the rena-
tured BRCA2BRC1–8 protein are thus in keeping with the pre-
dicted nature of this region of human BRCA2 (5).
BRCA2 BRC1–8 forms a ternary complex with RAD51
and DNA
Isolated BRC repeats can either prevent RAD51 nucleopro-
tein ﬁlaments (11) or form a ternary complex with RAD51
on DNA (13). We tested the ability of BRCA2BRC1–8–
RAD51 complexes to bind DNA, or the effect of
BRCA2BRC1–8 on RAD51–DNA complexes, by EMSA. As
expected, radiolabelled linear fX174 dsDNA (Figure 3,
lane 1) was retarded in its mobility by addition of RAD51,
marking formation of a nucleoprotein ﬁlament (lane 2).
Interestingly, pre-formed BRCA2BRC1–8–RAD51 complexes
induce a further, concentration-dependent retardation in the
mobility of the radiolabelled dsDNA (lanes 3–9). An apparent
plateau in retardation occurs at >2.8 mM of BRCA2BRC1–8
that may reﬂect saturation of binding. Addition of increasing
amounts of BRCA2BRC1–8 to pre-formed RAD51–DNA
complexes (lanes 10–16) reveals a similar retardation in the
mobility of the radiolabelled dsDNA. Retardation peaks at
1.7–3.3 mM BRCA2BRC1–8, with a slight decrease in retarda-
tion at 3.9 mM, whose signiﬁcance could not readily be ascer-
tained, because the BRCA2BRC1–8 fragment could not be
puriﬁed at higher concentrations. We speculate, however,
that this biochemical feature could reﬂect the proposal that
BRCA2 may not only deliver RAD51 for ﬁlament formation
at sites of recombinational repair, but also help to dissolve
RAD51 ﬁlaments following the completion of repair (16).
BRCA2BRC1–8 alone does not retard the mobility of radiola-
belled dsDNA (lanes 17 and 18), indicating that complex for-
mation with DNA occurs via RAD51. Thus, irrespective of
the order of addition, our ﬁndings are indicative of a ternary
complex in which BRCA2BRC1–8 binds to the RAD51–DNA
nucleoprotein ﬁlament.
Further evidence for ternary complex formation comes
from afﬁnity chromatography (Figure 4). A short, 73 bp
Figure 2. Circular dichroism spectroscopy of purified BRCA2BRC1–8.( A) A far UV spectrum recorded over the range 185–260 nm is indicative of a mixture of
secondary structural elements. Deconvolution of this spectrum using the CDSSTR algorithm indicates that the purified BRCA2BRC1–8 protein consists of 9%
a-helix, 33% b-sheet, 24% turns and 34% random coil (data were fitted with normalized r.m.s.d. of 0.031). This mixture of structured regions and flexible
unstructured sequence is consistent with the predicted nature of the exon 11 region of BRCA2 given its generally poor conservation in terms of sequence but
strong conservation in terms of inter-BRC repeat spacing between mammalian BRCA2 orthologues. (B) The differences between far UV spectra recorded over
the range 205–360 nm under native and denaturing (6 M guanidine–HCl) conditions confirm that the renatured BRCA2BRC1–8 sample does contain secondary
structural elements that are destroyed upon denaturation.
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logous circular 5386 bp fX174 ssDNA molecule in order to
create a biotinylated substrate, which predominantly represents
a ssDNA circle (Figure 4A). RAD51 and BRCA2BRC1–8 (either
alone or together, as indicated) were then incubated with
the DNA substrate. Proteins bound to the DNA-joint mole-
cule (labelled ‘b’ in the ﬁgure) were isolated by afﬁnity chro-
matography on magnetic-streptavidin beads, resolved by
SDS–PAGE, and revealed by protein staining. Unbound pro-
teins left behind in the supernatant (labelled ‘s’ in the ﬁgure)
were compared with proteins bound to the DNA-joint
molecules.
As expected, RAD51 alone binds efﬁciently to DNA-joint
molecules (Figure 4B, lanes 1 and 2), marking the formation
of a nucleoprotein ﬁlament. In the absence of RAD51, the
majority of BRCA2BRC1–8 remains in the supernatant
Figure 3. EMSA analysis of ternary complex formation between BRCA2BRC1–8, RAD51 and DNA. The BRCA2BRC1–8 fragment induces a concentration-
dependent shift in the mobility of RAD51/DNA complexes (lane 2) regardless of whether radiolabelled DNA is added to a pre-formed RAD51–BRCA2BRC1–8
complex (lanes 3–9), or BRCA2BRC1–8 is added to a pre-formed RAD51 filament on radiolabelled DNA (lanes 10–16). The dashed line marks the lower edge of
RAD51–DNA complexes (marked B for bound). The first lane shows the migration of radiolabelled dsDNA without added protein (marked UB for unbound).
Note that BRCA2BRC1–8 alone has no effect on the mobility of the radiolabelled dsDNA (lanes 17 and 18).
Figure 4. BRCA2BRC1–8 forms a ternary complex with RAD51 on DNA-joint molecules. (A) Schematic representation of the binding assay. Proteins were pre-
incubated in strand exchange buffer containing 1 mM AMP-PNP (Materials and Methods) at 37 C for 30 min, before the addition to different concentrations of
DNA-joint molecules bound to streptavidin-conjugated magnetic beads, and incubation for a further 30 min at 37 C. Proteins in the supernatant (s) were
separated from the protein–DNA complexes bound to the magnetic beads (b) before analysis by SDS–PAGE. (B) Binding of BRCA2BRC1–8 is dependent on
RAD51. SDS–PAGE analysis of proteins in the supernatant (s) or bound to DNA-joint molecules (b) is shown. DNA-joint molecules were incubated with
RAD51 (5 mM) alone (lanes 1 and 2), BRCA2BRC1–8 (2 mM) alone (lanes 3 and 4) or RAD51 with BRCA2BRC1–8 (lanes 5 and 6). (C) Ternary complex formation
between BRCA2BRC1–8 and RAD51 bound to DNA-joint molecules occurs at different ssDNA/RAD51 concentration ratios. Complex formation by RAD51
(5 mM) is shown at ssDNA/RAD51 ratios of 2:1 or 3:1 in the absence (lanes 1–4) or presence (lanes 5–8) of BRCA2BRC1–8 (2 mM). (D) Ternary complex
formation by RAD51 (5 mM) and DNA-joint molecules at an ssDNA/RAD51 ratio of 3:1 with increasing concentrations of BRCA2BRC1–8. Lanes 1 and 5
represent control reactions performed in the absence of BRCA2BRC1–8. The (s) and (b) fractions are indicated.
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binds to the DNA substrate (Figure 4B, lane 4). Since similar
levels of BRCA2BRC1–8 bind to the streptavidin beads alone
(data not shown), BRCA2BRC1–8 pull-down in this case likely
reﬂects a non-speciﬁc interaction with the beads rather than
DNA binding. Importantly, when RAD51 is present, the
majority of BRCA2BRC1–8 is brought down with the DNA-
joint molecule (Figure 4B, compare lanes 3 and 4 with 5
and 6). Ternary complex formation between BRCA2BRC1–8,
RAD51 and DNA was observed over a range of nucleotide/
protein concentration ratios, including 1:1 (data not shown),
2:1 and 3:1 (Figure 4C), at which RAD51 has been shown
previously to perform strand exchange in vitro (26).
This conclusion is further substantiated by the
concentration-dependent binding of BRCA2BRC1–8 to a
ﬁxed amount (5 mM) of the RAD51–DNA-joint molecule
complex formed at a nucleotide/protein concentration ratio
of 1:1 (Figure 4D). At 1 mM concentration, BRCA2BRC1–8
is entirely bound to the RAD51–DNA complex (compare
lanes 2 and 6), further conﬁrming the results in Figure 4B.
Increasing amounts of BRCA2BRC1–8 are pulled down with
the RAD51–DNA complex, reaching saturation at  3 mM
(compare lanes 3 and 7 versus 4 and 8). This is similar to
the results of EMSA shown in Figure 3B, where saturation
of binding occurs at 2.8–3.9 mM. Each BRCA2BRC1–8 mole-
cule contains multiple BRC repeats potentially capable of
binding RAD51 with varying afﬁnities (8,12). Thus, the
saturation we observe as the concentration of BRCA2BRC1–8
is increased could reﬂect intermolecular competition for bind-
ing to limiting amounts of RAD51, with only those BRC
repeats in each BRCA2BRC1–8 molecule that have the highest
afﬁnity for RAD51 able to bind when the BRCA2BRC1–8–
RAD51 molar ratio approaches 1:1.
Taken together, the ﬁndings we have presented in Figures 3
and 4 provide direct evidence that the multiple BRC repeat
region of BRCA2 can form a ternary complex with RAD51
on DNA rather than disrupting it. This is in contrast to the
apparently inhibitory effect of individual BRC repeats on
RAD51 nucleoprotein ﬁlament formation [(11) and data not
shown), suggesting that function of BRC repeats is modiﬁed
and directed when present as an eight-repeat unit within the
context of the exon 11 region.
BRCA2BRC1–8 promotes RAD51-mediated strand
exchange
The recombination function of RAD51 may be demonstrated
through its ability to perform strand exchange between circu-
lar ssDNA and linearized dsDNA (radiolabelled and non-
radiolabelled) in the presence of ssDNA-binding protein,
RPA (25–27) (Figure 5A). The strand exchange assay is
now well established as a method of demonstrating recombi-
nation in vitro, and has been used to study the recombination
functions of all RAD51 recombinases. Interestingly, whilst
E.coli RecA and yeast RAD51 are both highly active in
recombination, mammalian RAD51 is a relatively poor
recombinase when isolated in vitro (28–32). Clearly,
co-factors present in mammalian cell nuclei are required to
promote RAD51-mediated recombination that are not neces-
sary for the recombinase function of yeast and bacterial
RAD51 homologues.
In order to study RAD51-mediated strand exchange outside
its normal cellular environment, buffer systems have been
developed that optimally stimulate RAD51 recombinase
activity in vitro (25,33,34). Importantly, the addition of dif-
ferent ionic species stimulates the recombinase activity of
mammalian RAD51. It has been reported that the inclusion
of either (NH4)2SO4 or Ca
2+ in the reaction buffer enhances
RAD51-mediated strand exchange in vitro (25,33,34). This
has provided a useful tool for investigating the recombinase
activity of mammalian RAD51, which would otherwise be
difﬁcult to study. Consistent with these previous reports, we
ﬁnd that in the presence of ammonium sulphate, RAD51
mediates strand exchange in a concentration-dependent man-
ner with respect to DNA (Figure 5B and C) that is absolutely
dependent on RPA as has been reported previously (25).
Figure 5. RAD51-mediated strand exchange assay. (A) Schematic repre-
sentation of the strand exchange assay. (B) Stimulation of RAD51-mediated
strand exchange in the presence of (NH4)2SO4 requires RPA. Reaction
mixtures containing 100 mM (NH4)2SO4 were pre-incubated without (lanes 1
and 5) or with increasing concentration of RAD51 (lanes 2–4 and 6–8) and
ssDNA (30 mM) for 5 min followed by buffer control (lanes 1–4, no RPA) or
with RPA (1 mM; lanes 5–8) for another 5 min. Linear dsDNA (30 mM) was
added to stimulate strand exchange for a further 60 min. Reactions were
performed at 37 C. The reactions were de-proteinized and analysed by gel
electrophoresis and ethidium bromide staining. (C) Stimulation of RAD51-
mediated strand exchange as function of ssDNA titration. Reactions were set
up in the presence of (NH4)2SO4 and RPA as described in (B) except that the
RAD51 concentration was constant at 10 mM (lanes 2–7) in the absence
(lanes 1 and 2) or presence (lanes 3–7) of increasing concentration of ssDNA.
Linear dsDNA was present at 10 mM. The reactions products were analysed
as described previously. The ssDNA/RAD51 ratio is as indicated.
4006 Nucleic Acids Research, 2006, Vol. 34, No. 14Similarly, RAD51 is effective at strand exchange in the pre-
sence of 0.3–0.6 mM Ca
2+, also as reported previously (data
not shown).
However, the conditions used in these in vitro assays for
RAD51-mediated strand exchange do not conform to the
ionic milieu found within the mammalian cell nucleus, in
which K
+ and Mg
2+ are the predominant ionic species
(35–38). Indeed, there is structural evidence that K
+ may
modulate the ATPase activity of an archael homologue of
RAD51 (39). Accordingly, we performed experiments under
approximately physiological conditions (200 mM K
+ and
1m MM g
2+), in the absence of ammonium or calcium ions,
and in the presence of an ATP regenerating system (34).The
concentration of RPA in the reaction was also adjusted so that
the need for the BRCA2CTD, which is required to displace
RPA, was obviated (18,40).
At ssDNA/RAD51 ratio of 3:1, RAD51 was found to
weakly stimulate strand exchange, as has been reported pre-
viously (Figure 6A, lane 1) (34). However, upon the addition
of BRCA2BRC1–8, RAD51-mediated strand exchange was
robustly stimulated in a dose-dependent manner, with the for-
mation of joint molecule and complete recombination
products in the form of nicked circles (Figure 6A, lanes
2–4). BRCA2BRC1–8 stimulated strand exchange when pre-
sent at one-ﬁfth of the concentration of RAD51 (Figure 6A,
lane 2). Efﬁcient formation of a ternary complex with
RAD51 and DNA is observed at a non-saturating concentra-
tion of BRCA2BRC1–8 (Figure 4D, lane 6) which would sug-
gest that the binding of RAD51 is thus likely to involve
multiple BRC repeats of each BRCA2BRC1–8 molecule. Sti-
mulation of strand exchange by BRCA2BRC1–8 is also clearly
dependent upon the presence of Mg
2+ and ATP (Figure 6B).
We observe a stimulatory effect of  3 mM BRCA2BRC1–8
on RAD51-mediated strand exchange, equating to  24 mMo f
single BRC repeats. However, under the same conditions, an
equivalent concentration of isolated BRC4 peptide inhibits,
rather than promotes, strand exchange (Figure 6C), consistent
with its ability to inhibit RAD51 nucleoprotein formation
[(11) and data not shown]. This suggests that the eight
BRC repeats, when organized in the context of the
BRCA2BRC1–8 fragment, may possess an activity not shared
with isolated BRC peptides. However, given the differences
in sequence between the different BRC repeats in human
BRCA2, which are poorly characterized in terms of function,
further investigation is warranted.
Another ion found in the mammalian nucleus is Ca
2+,
which is reportedly present at concentrations of  0.1 mM
free Ca
2+ (41), although higher local concentrations might
be achieved during biological signalling. Although Ca
2+
alone at 0.3–0.6 mM can stimulate RAD51-mediated strand
exchange in vitro [(33) and data not shown], we ﬁnd that
when physiological concentrations of K
+ and Mg
2+ are also
present, RAD51 activity is relatively low (Figure 6D, com-
pare lane 1 with lanes 2–5). However, under these conditions,
a sub-stoichiometric amount of BRCA2BRC1–8 provided a
substantial stimulus to the strand exchange reaction
(Figure 6D, compare lane 6 with lanes 7–10). Thus, in an
ionic milieu approaching the physiological conditions of the
mammalian nucleus, we ﬁnd that whilst recombinase activity
of RAD51 diminishes, the level of stimulation achieved by
BRCA2BRC1–8 greatly increases.
We have demonstrated that, at the 3:1 DNA/RAD51 ratio
used in the strand exchange assays, BRCA2BRC1–8 forms a
ternary complex involving RAD51 and ssDNA (Figures 3
and 4), which plausibly represents the species active in stimu-
lating strand exchange. However, to rule out the possibility
that BRCA2BRC1–8 promotes strand exchange by sequestering
RAD51 away from the linear dsDNA used in these reactions,
we examined the ability of RAD51 to promote strand
exchange—in the absence or presence of an increasing con-
centration of BRCA2BRC1–8—at different DNA/RAD51
ratios ranging from 1:1 to 5:1 (Figure 6E). If BRCA2BRC1–8
were simply serving as a sink for free RAD51, this experi-
ment should reveal an increase in strand exchange by
RAD51 alone as the DNA/RAD51 ratio increases. This
does not occur. Instead, we ﬁnd that BRCA2BRC1–8 stimulates
strand exchange best when the DNA/RAD51 ratio is between
1:1 and 3:1, the same optimum reported with RAD51 alone,
but under different ionic conditions in which species such as
NHþ
4 (25) and Ca
2+ (33) substitute for BRCA2BRC1–8.
Collectively, our ﬁndings have two important implications.
First, they highlight an interesting difference between the
high-RAD51 activity under the relatively non-physiological
conditions so far used in vitro and its markedly diminished
capacity to mediate strand exchange in ionic conditions
more typical of the mammalian nucleus. We infer from our
work that in vivo, additional co-factors such as BRCA2 are
essential for efﬁcient homologous recombination mediated
by RAD51. This is entirely consistent with the cellular effects
of BRCA2 inactivation on DNA repair or chromosomal
integrity (1–3), and on homology-mediated gene conversion
(4,42).
Moreover, the experiments we report here demonstrate a
role for the multi-BRC repeat region conserved in all mam-
malian BRCA2 molecules, which is independent of the
BRCA2CTD. The DNA-binding BRCA2CTD has been shown
to stimulate RAD51-mediated strand exchange in vitro; its
role is believed to involve a displacement of RPA from
single-stranded DNA in order to allow RAD51 to bind
(18,40,43). However, we ﬁnd that when RPA concentrations
are lowered to obviate the need for its displacement by the
BRCA2CTD, a previously unrecognized activity of
BRCA2BRC1–8 in directly promoting RAD51-mediated strand
exchange is revealed. Thus, our ﬁndings also establish a bio-
logical function for the evolutionarily conserved region of
BRCA2 containing the eight BRC repeats.
DISCUSSION
In this paper we describe a signiﬁcant advance in understand-
ing the role of mammalian BRCA2 in homologous recombi-
nation. We have expressed and puriﬁed a 1127 amino acid
region of human BRCA2 containing all 8 BRC repeats
(BRCA2BRC1–8), and have demonstrated that as a collective
unit, the multiple BRC repeats can associate in a ternary com-
plex with RAD51 on ssDNA and dsDNA. Ternary complex
formation and the stimulation of RAD51-mediated strand
exchange occur at sub-stoichiometric concentrations of
BRCA2BRC1–8 relative to RAD51, indicating that each
BRCA2BRC1–8 molecule probably binds several molecules
of RAD51.
Nucleic Acids Research, 2006, Vol. 34, No. 14 4007Figure 6. Stimulation of RAD51-mediated strand exchange by BRCA2BRC1–8.( A) Stimulation of RAD51-mediated strand exchange by BRCA2BRC1–8 in the
presence of KCl and Mg
2+. Reactions were carried out using ssDNA and RAD51 at a ratio of 3:1. RAD51 was pre-incubated without (lane 1) or with increasing
concentrations of BRCA2BRC1–8 (lanes 2–4) for 5 min before adding ssDNA and RPA (0.26 mM). After a further 5 min incubation, radiolabelled linear dsDNA
(10 mM) was added and incubated for a further 60 min. The reactions steps were incubated at 37 C. The strand exchange products were analysed by gel
electophoresis and phosphoimager. (B) Stimulation of RAD51-mediated strand exchange by BRCA2BRC1–8 is dependent on Mg
2+ and ATP. Reactions were
carried out as described in (A) either in the absence of both co-factors Mg
2+ and ATP (lanes 1–4), in the absence of ATP but presence of Mg
2+ (lanes 5–8) or in
the presence of both co-factors (lanes 9–12). BRCA2BRC1–8 was present as indicated. (C) Effect of BRCA2BRC1–8 (lane 2) or isolated BRC4 peptide (lane 3) on
RAD51-mediated strand exchange when BRC repeats are present at equivalent molarities. Reactions were carried out as in (A). The first lane shows a reaction
without added proteins. (D) The effect of BRCA2BRC1–8 on RAD51-mediated strand exchange is not dependent on physiologically relevant Ca
2+ concentrations.
Reactions are as described in (B) except that RAD51, either in the absence (lanes 1–5) or presence of BRCA2BRC1–8 (2 mM; lanes 6–10), was incubated with
buffer containing no Ca
2+ ions (lanes 1 and 6) or an increasing concentration of Ca
2+ (lanes 2–5 and 7–10). (E) BRCA2BRC1–8 stimulates RAD51-mediated strand
exchange at different DNA/RAD51 ratios. Reactions are as described in (A).
4008 Nucleic Acids Research, 2006, Vol. 34, No. 14We have further shown that BRCA2BRC1–8 stimulates
RAD51-dependent strand exchange under physiologically
relevant conditions in which human RAD51 shows only
poor recombinase activity. Crucially, our description of a
novel function for the BRC repeat region of mammalian
BRCA2, does not depend on the BRCA2CTD. Previous
work had shown stimulation of strand exchange by the Mus
musculus BRCA2CTD, the U.maydis BRCA2 homologue
Brh2 containing a CTD and single BRC repeat and
the human BRC3–4 fused to a CTD (18,40,43). Our results
establish BRCA2BRC1–8 as a co-factor necessary to promote
RAD51-dependent homologous recombination under physio-
logical conditions resembling those present in the nuclei
of living cells, consistent with the known importance of
BRCA2 to homologous recombination in vivo.
Our data are consistent with a model (11,16) inferred from
the observations that BRCA2 is complexed to RAD51 even
before DNA damage (44) and is required to target RAD51
to sites of DNA damage (2,14,16) protected by RPA (45)
in preparation for homologous recombination (Figure 7).
Thus, BRCA2 is expected to function both in sequestering
RAD51 to prevent promiscuous ﬁlament formation in unda-
maged cells, and in targeting and promoting RAD51’s recom-
binase function at sites of DNA damage, perhaps as a result
of activation by post-translational modiﬁcations (15,16). At
sites of damage, BRCA2 is likely to perform multiples func-
tions in promoting RAD51-mediated homologous recombina-
tion (Figure 7). The displacement of RPA by the BRCA2CTD
may arrange the exon 11-BRC repeat-bound RAD51 mole-
cules in a manner conducive to their loading on to damaged
DNA for nucleoprotein ﬁlament formation (Figure 7). Indeed,
whilst the in vitro strand exchange reaction presented here
does not depend on the DNA-binding BRCA2CTD, it is likely
that in vivo, the CTD helps, not only to target the active
BRCA2–RAD51 complex to junctions between ssDNA and
dsDNA (18) but also to orientate the complex with respect
to the polarity of the resected double-strand break.
Our proposal for the function of the multiple BRC repeats
within the exon 11 region is supported by the ﬁnding that
under speciﬁc conditions, BRC3 and BRC4 can associate
with a nucleoprotein ﬁlament without causing its disruption
(13). Given the known antagonism between the BRC
repeat–RAD51 interaction and RAD51 oligomerization, this
might conceivably be explained by BRC repeats possessing
two modes of RAD51 binding, one that is inhibitory to
ﬁlament formation (12) and another that is compatible with
ﬁlament formation (13), reﬂecting the duality of the function
of BRCA2 in regulating RAD51 activity during homologous
recombination (11,15). BRC repeats may thus interact with a
RAD51 ﬁlament as a ternary complex if present in sub-
stoichiometric amounts, but then disrupt the ﬁlament through
their inhibitory binding mode if present in excess (11,13,40).
The large exon 11 sequence that houses the eight BRC
repeats would thus be expected to control the binding mode
of the BRC repeats, allowing them to form a ternary complex
with RAD51 and DNA, as described in this study.
However, it is also possible that the inhibition and the
stimulation of RAD51 activity by BRCA2 reﬂect only a
single mode of BRC repeat-RAD51 binding, and not two dis-
tinct modes. One major difﬁculty with the hypothesis of a
second mode of binding of the BRC repeat to RAD51 (13)
lies in the observation that the amino acid conservation
within BRC repeats is already accounted for by the known
inhibitory interaction between BRC repeats and RAD51
through mimicry of self-association (12,19,46). It would
therefore be surprising for a second RAD51-binding mode
Figure 7. A model for the multiple roles of BRCA2 in regulating RAD51-mediated homologous recombination BRCA2 sequesters RAD51 in an inactive complex
in undamagedcells.FollowingDNAdamage,the activatedBRCA2–RAD51complexis targetedviathe C-terminaldomain(CTD)to thelinear-duplexDNA ofthe
RPA-coated,resectedsingle-strandedends.TheCTDisessentialtodisplaceRPA,enablingtheBRCA2–RAD51complextobindDNAtoformtheternarycomplex
demonstrated here (Figures 3 and 4). This may help to orient the BRCA2–RAD51 complex with respect to the polarity of the resected double-strand break. Our
results(Figure6)suggestthatthemulti-BRCrepeatregionofBRCA2canstimulateRAD51-mediatedstrandexchange,distinctfromtheRPA-displacingactivityof
the CTD, a novel activity that promotes homologous recombination. We speculate that stimulation of strand exchange involves the same mode of RAD51–BRC
repeat binding as in the inactive complex, with each BRC repeat capping one self-association surface of RAD51, but permitting filament growth from its opposite
surface (circled inset). The resulting nucleoprotein filament might thus consist of multiple RAD51 multimers separated by interleaved BRC repeats.
Nucleic Acids Research, 2006, Vol. 34, No. 14 4009to have emerged for BRC repeats with a similar pattern of
sequence conservation as that of the ﬁrst binding mode.
We therefore favour an alternative explanation for the sti-
mulation of RAD51-mediated strand exchange by BRCA2,
which does not invoke a second binding mode. We envision
that the BRC repeats of BRCA2BRC1–8 bind RAD51 in only
one mode, inhibitory of RAD51 oligomerization, with each
BRC repeat capping one self-association surface of RAD51,
but permitting ﬁlament growth from its opposite surface
(Figure 7 circled inset). The resulting nucleoprotein ﬁlament
would thus consist of multiple ﬁlaments separated by inter-
leaved BRC repeats. Indeed, the long exon 11 sequence
between adjacent BRC repeats would allow for considerable
growth of each capped ﬁlament. It is important to note,
however, that our results are consistent with either of
these structural possibilities explaining the novel activity
of BRCA2BRC1–8 in promoting RAD51-mediated strand
exchange.
In summary, we have established a unique tool for research
into mammalian homologous recombination through the
expression and puriﬁcation of BRCA2BRC1–8, a fragment of
BRCA2 containing all eight BRC repeats. We report that
within the context of the wider sequence provided by
BRCA2BRC1–8, the eight BRC repeats exert a previously
unrecognized, collective function in promoting RAD51-
mediated strand exchange through ternary complex forma-
tion, independent of the BRCA2 C-terminal domain. Thus,
our work provides direct biochemical evidence that human
BRCA2 can function as a recombination mediator—a critical
but unresolved issue (17). The identiﬁcation of a mechanism
for the stimulation of RAD51-mediated recombination by the
multiple BRC repeat-containing region of human BRCA2
provides an important insight into the process of recombina-
tional DNA repair in mammalian cells.
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